This study is in progress, not accepting new patients
A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy
Summary
- Eligibility
- for people ages 18-99 (full criteria)
- Location
- at UCLA UCSD
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- AbbVie
- ID
- NCT02141282
- Phase
- Phase 2
- Study Type
- Interventional
- Last Updated